Experimental Study On Effects Of Raloxifen And CCP On Bone In OVX Rats Model

Postmenopausal osteoporosis (PMO) is a prevalent metabolic bone disease which threatens the health of elder women seriously. It can increase the risk of fracture. Although estrogen replacement therapy has been widely used to cure and prevent PMO, adverse effects of this method on patient's health limits its application for PMO. Raloxifene is a novel type of medicine-selective estrogen receptor modulators (SERMs). SERMs are safe and have protective effects on hard tissue. On the other hand, many clinical trials showed cervus and cucumis polypeptide (CCP) could induce new bone formation, accelerate osteogenesis and promote fracture repairing as well. Based on this theory, we established an animal model of PMO using rats by ovariectomy (OVX) to investigate following items: (1) Influence of Raloxifene on expression of TNF-a in cancellous bone in OVX rats. (2) Effects of Raloxifene on bone mineral density, bone biomechanical property and bone metabolism in OVX rats. (3) Influence of CCP on expression of BMP₂ in cancellous bone and bone mineral density in PMO models.With an attempt to investigate the mechanism of Raloxifen and CCP on bone tissue, the experiments were designed. (1). Thirty female SD rats...